Selective Reduction of Halogenated Nitroarenes with Hydrazine Hydrate in the Presence of Pd/C
摘要:
A large variety of halogenated nitroarenes have been selectively reduced with hydrazine hydrate in the presence of Pd/C to give the corresponding (halogenated) anilines in good yield.
[EN] MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS<br/>[FR] ANTIBIOTIQUES MACROCYCLIQUES À LARGE SPECTRE
申请人:RQX PHARMACEUTICALS INC
公开号:WO2018149419A1
公开(公告)日:2018-08-23
Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
[EN] ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C<br/>[FR] POLYTHÉRAPIE ANTICANCÉREUSE AVEC UN INHIBITEUR DE N-(1-ACRYLOYL-AZÉTIDIN-3-YL)-2-((1H-INDAZOL-3-YL) AMINO) MÉTHYL)-1 H-IMIDAZOLE-5-CARBOXAMIDE DE KRAS-G12C
申请人:TAIHO PHARMACEUTICAL CO LTD
公开号:WO2021215545A1
公开(公告)日:2021-10-28
A method of treating cancer comprises administering: (a) a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof; and (b) a therapeutically effective amount of an additional anti-cancer agent, to a subject in need of such treatment, the compound of Formula (I) being: where X, R1, R2, ring A, L1, L2, L3, and R5 are as defined in this disclosure.
Palladium-catalyzed remote C–H functionalization of 2-aminopyrimidines
作者:Animesh Das、Akash Jana、Biplab Maji
DOI:10.1039/d0cc00575d
日期:——
A straightforward strategy was developed for the arylation and olefination at the C5-position of the N-(alkyl)pyrimidin-2-amine core with readily available aryl halides and alkenes, respectively. This approach was highly regioselective, and the transformation was achieved based on two different (Pd(ii)/Pd(iv)) and (Pd(0)/Pd(ii)) catalytic cycles.
[EN] AMINOPYRIMIDINONES AS INTERLEUKIN RECEPTOR-ASSOCIATED KINASE INHIBITORS<br/>[FR] AMINOPYRIMIDINONES EN TANT QU'INHIBITEURS DE KINASES ASSOCIÉES AU RÉCEPTEUR DE L'INTERLEUKINE
申请人:MERCK SHARP & DOHME
公开号:WO2013066729A1
公开(公告)日:2013-05-10
This invention relates to aminopyrimidinone compounds of Formula (I) that are inhibitors of Interleukin receptor-associated kinases, in particular IRAK-4, and are useful in the treatment or prevention of inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease.
The present invention relates to novel dihydropyrones with tethered heterocycles having improved pharmacologic properties which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for the treatment of viral infections and diseases, including AIDS. The present invention is also directed to methods of synthesis of the dihydropyrones and intermediates useful in the preparation of the final compounds.